On October 24, 2019 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") reported that it will a host a conference call and webcast to highlight interim results from the pivotal Phase 3 SIERRA trial for its lead program, Iomab-B (Press release, Actinium Pharmaceuticals, OCT 24, 2019, View Source [SID1234542471]). The SIERRA trial (Study of Iomab-B in Elderly Relapse Refractory Acute Myeloid Leukemia) is a 150-patient, randomized 1:1 pivotal Phase 3 trial that is studying Iomab-B compared to physician’s choice of salvage chemotherapy in patients age 55 and above with active, relapsed or refractory AML or acute myeloid leukemia. The SIERRA trial is the only randomized Phase 3 trial to offer BMT, the only potentially curative treatment option, to this patient population.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The SIERRA trial reached 50 percent enrollment in July 2019. The call will highlight findings from the first 50 percent of patients in the SIERRA trial.

Conference Call and Webcast Details:
Time and Date: 12:00 PM ET on Monday, October 28th
Webcast link: View Source
U.S./Canada Toll Free Dial-in: (855) 698-6739
Participant Dial-in: (646) 402-9440
Conference ID: 0417

About Iomab-B

Iomab-B is an ARC or Antibody Radiation-Conjugate comprised of the anti-CD45 antibody apamistamab and the radioisotope iodine-131 that is intended to be a targeted conditioning agent prior to a BMT or bone marrow transplant. Iomab-B was developed at the Fred Hutchinson Cancer Research Center and has been studied in over 300 patients in multiple hematologic indications across 12 clinical trials in addition to the ongoing SIERRA study in older patients with active, relapsed or refractory AML or Acute Myeloid Leukemia prior to patients receiving an allogeneic BMT or bone marrow transplant. Iomab-B is Actinium’s lead targeting conditioning ARC in its multi-target, multi-indication targeted conditioning pipeline that includes the Iomab-B and Actimab-MDS programs for BMT and the Iomab-ACT program that will study a lower dose of Iomab-B for lymphodepletion prior to CAR-T and other cellular therapies.